SCH-900776 is an inhibitor of checkpoint kinase 1 (Chk1) that exhibits anticancer chemotherapeutic activity. SCH-900776 is currently in clinical trials as a potential co-administered treatment for cancer. With other chemotherapeutics, SCH-900776 induces double-stranded DNA strand breaks and cell death.
| Cas No. | 891494-63-6 |
|---|---|
| Purity | ≥98% |
| Formula | C15H18BrN7 |
| Formula Wt. | 376.25 |
| IUPAC Name | 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine |
| Appearance | Pale yellow powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | S0928 Info Sheet PDF |
|---|
Dai Y, Chen S, Kmieciak M, et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther. 2013 Jun;12(6):878-89. PMID: 23536721.
Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. PMID: 23092873.
Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. PMID: 21321066.
